Leesa Gentry
CIK: 0002013097
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
RNXT
RenovoRx, Inc.
Officer
Discretionary Trading P&L
Holdings
About Gentry Leesa
Gentry Leesa (SEC CIK 0002013097) files insider reports with the SEC as Chief Clinical Officer of RenovoRx, Inc. (RNXT).
Signal8 holds 3 ownership filings by Gentry Leesa, all Form 4s, filed between Apr 16, 2025 and Apr 7, 2026. Those filings report 3 transactions, from Apr 14, 2025 to Apr 3, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Gentry Leesa's filings is in MOUNTAIN VIEW, CA.
Recent filings by Gentry Leesa
Other insiders filing for RenovoRx, Inc. (RNXT)
- Macfarlane K. Angela, Director
- Spiegel Robert J., Director
- RYAN UNA S, Director
- Marton Laurence, Director
- VOLL MARK, Chief Financial Officer
- Bagai Shaun, Chief Executive Officer